Log in to save to my catalogue

Efficacy of the Anti-CD22 Recombinant Immunotoxin BL22 in Chemotherapy-Resistant Hairy-Cell Leukemia

Efficacy of the Anti-CD22 Recombinant Immunotoxin BL22 in Chemotherapy-Resistant Hairy-Cell Leukemia

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_miscellaneous_17892034

Efficacy of the Anti-CD22 Recombinant Immunotoxin BL22 in Chemotherapy-Resistant Hairy-Cell Leukemia

About this item

Full title

Efficacy of the Anti-CD22 Recombinant Immunotoxin BL22 in Chemotherapy-Resistant Hairy-Cell Leukemia

Publisher

Boston, MA: Massachusetts Medical Society

Journal title

The New England journal of medicine, 2001-07, Vol.345 (4), p.241-247

Language

English

Formats

Publication information

Publisher

Boston, MA: Massachusetts Medical Society

More information

Scope and Contents

Contents

A genetically engineered molecule to treat resistant hairy-cell leukemia.
About 2 percent of cases of leukemia are of the hairy-cell type.
1
,
2
Prominent features of the disease are splenomegaly, pancytopenia, and the presence of cells in the peripheral blood, spleen, and bone marrow with hair-like cytoplasmic projections.
3
,...

Alternative Titles

Full title

Efficacy of the Anti-CD22 Recombinant Immunotoxin BL22 in Chemotherapy-Resistant Hairy-Cell Leukemia

Identifiers

Primary Identifiers

Record Identifier

TN_cdi_proquest_miscellaneous_17892034

Permalink

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_miscellaneous_17892034

Other Identifiers

ISSN

0028-4793

E-ISSN

1533-4406

DOI

10.1056/NEJM200107263450402

How to access this item